Clinical Trials Logo

Bacterial Resistance clinical trials

View clinical trials related to Bacterial Resistance.

Filter by:
  • None
  • Page 1

NCT ID: NCT05939479 Completed - Clinical trials for Bacterial Resistance

Antistaphylococcal Betalactam and Emergence of Resistance

CePasR
Start date: January 1, 2018
Phase:
Study type: Observational

Antistaphylococcal penicillins are recommanded as first-line agent in methicillin-suceptible Staphylococcus aureus bacteraemia. Several studies in progress are investigating the efficacy and safety of cefazolin compared with antistaphylococcal penicillins. Cefazolin has broader spectrum than antistaphylococcal penicillins. The hypothesis of this project is that cefazoline could be responsible for a higher rate of bacterial resistance. The aim is to study the association between the emergence of bacterial resistance and the consumption of cefazolin and antistaphylococcal penicillins.

NCT ID: NCT03998865 Completed - Clinical trials for Peri-implant Mucositis

Bacterial Microbiota Characterization on Implant-supported PEEK and Titanium Provisional Abutments

Start date: May 8, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to determine the relative abundances of the different bacterial phyla and families in the microbiota present on the surface of PEEK implant-supported provisional abutments compared to titanium implant-supported provisional abutments, as well as the effect of both materials on the presence of antibiotics resistance genes.

NCT ID: NCT03752476 Not yet recruiting - Clinical trials for Antibiotic Resistant Infection

Impact of Number of Rank of B-lactam Antibiotics on Emergence on Multidrug Resistant Bacteria

INOR Blact
Start date: January 1, 2019
Phase:
Study type: Observational

This study evaluates the impact of rank of Beta lactam antibiotics on emergence of mutlidrug resistant bacteria colonization in intensive care It's retrospective case controle study. Cases are colonized patient by multidrug resistant bacteria hospitalized in intensive care during the fist hospitalization in intensive care. Temoin are patients with the same characteristics than case but no colonized by multidrug resistant bacteria.

NCT ID: NCT03226314 Active, not recruiting - Clinical trials for Bacterial Resistance

Community Epidemiology and Typology of Third-generation Cephalosporins Resistant Enterobacteriaceae in Reunion Island

AB-RUN
Start date: November 21, 2017
Phase:
Study type: Observational

In its report dated april 2014, World Health Organization confirms antibiotic resistance dissemination in all parts of the world, in hospitals and in community and worries about a possible comeback to a pre-antibiotic era during the 21st century. For the last 15 years, third-generation cephalosporins resistant enterobacteriaceae (3GCREB) prevalence is continuously increasing. Community 3GCREB prevalence has not been studied whereas several observations made in Reunion Island hospital suggest a diffusion in community. In this situation of world-wide and regional extension of bacterial resistance, the investigator offers to study bacterial resistance to antibiotic in Reunion Island community.

NCT ID: NCT02641015 Completed - Clinical trials for Urinary Tract Infections

Study to Assess Management and Outcomes of Hospitalised Patients With Complicated UTI (RESCUING)

RESCUING
Start date: December 2015
Phase: N/A
Study type: Observational

A retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant gram-negative bacteria (COMBACTE-MAGNET,WP5)

NCT ID: NCT02223338 Completed - Clinical trials for Bacterial Resistance

Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics

Start date: October 2014
Phase: N/A
Study type: Interventional

1. Background: Over 1 million intravitreal injections are performed annually in the United States. The most devastating complication related to these injections is endophthalmitis, with an incidence of 0.02 - 0.1% per injection. Techniques aimed at prevention of this complication have been studied, though emergence rates of antibiotic resistant bacteria in a single clinic population comparing antiseptic technique with iodine vs. use of post-injection second generation fluoroquinolones has not been reported in the literature. 2. Objectives: The purpose of the study is to help determine the best way to prevent infection and limit antibiotic resistance in patients receiving eye injections. 3. Procedures Involved (Research Interventions): After the patient is chosen based on inclusion criteria and agrees to participate in the study, exclusion criteria will be reviewed, cognizance will be determined, informed consent and HIPAA compliance forms will be signed. At this point and prior to the instillation of ophthalmic medications, a Rayon swab will be passed along the inferior fornix of the study eye while the patient looks up and the examiner lowers the lower eyelid. The swab will then be used to inoculate chocolate agar and a blood agar culture plates and a glass slide. These will be brought to the FMO microbiology department for culture and Gram stain. All Staphylococcus aureus and coagulase negative Staphylococcus species identified will be subjected to sensitivity testing using the Gram Positive antibiotic panel available at Loma Linda, with the addition of ciprofloxacin.

NCT ID: NCT01878643 Completed - Respiratory Failure Clinical Trials

Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit

Start date: December 2001
Phase: Phase 0
Study type: Interventional

The purpose of this study was : - to determine the effect of inhaled antibiotics on airway bacteria in ventilated patients - to determine the effect of inhaled antibiotics on respiratory infection

NCT ID: NCT01208519 Active, not recruiting - Clinical trials for Bacterial Resistance

SATURN 04 Nosocomial Acquisition Study

SATURN
Start date: November 2010
Phase: N/A
Study type: Observational

The study is the WP4 of the EU-funded (7th FW) project SATURN (Impact of Specific Antibiotic Therapies on the prevalence of hUman host ResistaNt bacteria). A total of 6 surgical and 6 medical wards will participate in the study. Sites of the study are located in 3 countries (Italy, Serbia, Romania). This WP will compare nosocomial acquisition rates of methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamase (ESBL)-producing gram-negative bacteria (E.coli, Klebsiella spp. and Proteus spp.) among different treatment groups and define the temporal relationship between the start of antibiotic therapy, the acquisition of new colonisation in patients previously not colonised, and the development of a bacterial infection caused by the same strain isolated in a screening sample. This goal will be achieved by completing the following primary objectives: - To determine the rate of acquisition of target antibiotic-resistant bacteria by 1,000 antibiotic-days according to different classes of antibiotics, duration of therapy and antibiotic combination (monotherapy versus combination therapy); - To determine genotypic relation between colonising and infecting strain in the same patient and patients' and hospital staff colonising strains (to be performed in collaboration with WP1 of the SATURN project); - To study the virulence and fitness of the isolates (i.e. new colonising strains) causing subsequent nosocomial infections (to be performed in collaboration with WP1 of SATURN project); - To predict the risk for nosocomial infections due to target bacteria after a single treatment therapy adjusted by length of hospitalisation and ward colonisation pressure.